In light of the failure of Right to Try bill in The House, some background here: "Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits" https://teapawt.org/t.co/OZeGE9GXQV by @LiaTsimberidou et al from @MDAndersonNews #rightotry #openaccess
Expert Opinion on Investigational Drugs retweeted
Cefiderocol, a cephalosprin which targets siderophore uptake, suggested to have the potential to become first-line therapy for our most aggressive and lethal multidrug-resistant Gram-negative pathogens ncbi.nlm.nih.gov/pubmed/2931…
Paper on discontinued #Alzheimer's drugs is particularly relevant today: "Why are they failing? Is the treatment of symptomatic dementia too late? Are the therapeutic targets incorrect? Are the clinical methodologies imprecise, misleading, or inaccurate?" https://teapawt.org/t.co/d1OgWgUXwZ teapawt.org/bbchealth/status/95106…
Pharma giant pulls out of research into neuroscience bbc.in/2DfKtFK
Great to see @EnriqueSoto8 and @smlichtman_md's editorial "Considerations for clinical trial design in older adults with cancer" being featured in the #HemeAging session at last month's American Society of Hematology 2017 Annual Meeting #ASH17 #GeriOnc teapawt.org/Kristel_GT/status/9400…
Agree with @MelissaLoh21 .....@EnriqueSoto8's work being highlighted during the #hemeaging session #ash17 #siog #GeriOnc #youngsiog ncbi.nlm.nih.gov/m/pubmed/28… …
Expert Opinion on Investigational Drugs retweeted
BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations tandfonline.com/doi/full/10.…
Endoglin and ALK1 as therapeutic targets for hereditary hemorrhagic telangiectasia written by Ruiz-Llorente et al (@CIBERER) is Open Access and available here at Expert Opinion on Therapeutic Targets: https://teapawt.org/t.co/TO34zvkGu2
Interesting perspective on an emerging field - Investigational PD-1 inhibitors for advanced non-small lung cancer, new players in a shifting paradigm. Free to read editorial by Ghanem et al from @NorthwellHealth, available here: https://teapawt.org/t.co/YC8bqZvRuc
Editorial by @EnriqueSoto8 & @smlichtman_md - "Considerations for clinical trial design in older adults with cancer" is free to view online! teapawt.org/EnriqueSoto8/status/89…
An honor to write this editorial w/ @SIOGorg pres @smlichtman_md @ExpertOpinion on Investigational Drugs! #gerionc tandfonline.com/doi/abs/10.1…
BI 695502, US- & EU-approved Avastin showed 3-way bioequivalence with similar safety profile. Free access to trial - https://teapawt.org/t.co/dNXPYqoEPe
Expert Opinion on Investigational Drugs retweeted
SLEEP disturbances & severe STRESS as GLIAL activators: psychoneuroimmunology model explaining central sensitization ncbi.nlm.nih.gov/pubmed/2868…
Phase I trial assessing the bioequivalence of BI 695502, a bevacizumab biosimilar candidate. Free to access - https://teapawt.org/t.co/dNXPYqoEPe
Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 https://teapawt.org/t.co/K05V1hpAOb
Review - Preclinical to Phase II Amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease https://teapawt.org/t.co/FQGkuwjsGy
Review article - MERS-CoV spike protein: a key target for antivirals. Free to view until end of April. https://teapawt.org/t.co/3tk5EmVjiq
Read about accessory gene regulator-1 as a therapeutic target for C. difficile infection in this free editorial: https://teapawt.org/t.co/RXKigP2vTZ
Review article - Drugs in clinical development for the treatment of amyotrophic lateral sclerosis (ALS) https://teapawt.org/t.co/ztiYyTKrd0
Read about the latest investigational drugs for head and neck #cancer in this recently published #free #editorial https://teapawt.org/t.co/YANLP4lTuJ
An interesting new review recently published in Expert Opinion on Therapeutic Targets teapawt.org/ExpertOpinion/status/8…
This Post is from a suspended account. Learn more
Read this #free to view #editorial on KCC3 cotransporter as a therapeutic target for peripheral neuropathy... https://teapawt.org/t.co/hKQIZOdhOV











